Geode Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.6M | Buy |
604,180
+559,860
| +1,263% | +$29M | ﹤0.01% | 1767 |
|
|
2026
Q1 | $2.13M | Sell |
44,320
-1,463
| -3% | -$64.8K | ﹤0.01% | 3093 |
|
|
2025
Q4 | $1.89M | Buy |
45,783
+221
| +0.5% | +$8.87K | ﹤0.01% | 3191 |
|
|
2025
Q3 | $1.77M | Sell |
45,562
-5,380
| -11% | -$175K | ﹤0.01% | 3217 |
|
|
2025
Q2 | $1.41M | Sell |
50,942
-454,509
| -90% | -$11.6M | ﹤0.01% | 3233 |
|
|
2025
Q1 | $11.2M | Buy |
505,451
+12,821
| +3% | +$264K | ﹤0.01% | 2216 |
|
|
2024
Q4 | $9.74M | Buy |
492,630
+9,654
| +2% | +$220K | ﹤0.01% | 2398 |
|
|
2024
Q3 | $12.1M | Sell |
482,976
-365,918
| -43% | -$8.91M | ﹤0.01% | 2270 |
|
|
2024
Q2 | $15.8M | Buy |
848,894
+123,383
| +17% | +$2.31M | ﹤0.01% | 2058 |
|
|
2024
Q1 | $14.3M | Buy |
725,511
+25,898
| +4% | +$506K | ﹤0.01% | 2114 |
|
|
2023
Q4 | $12.3M | Buy |
699,613
+40,044
| +6% | +$658K | ﹤0.01% | 2222 |
|
|
2023
Q3 | $11.5M | Buy |
659,569
+46,917
| +8% | +$790K | ﹤0.01% | 2178 |
|
|
2023
Q2 | $8.63M | Buy |
612,652
+43,323
| +8% | +$580K | ﹤0.01% | 2375 |
|
|
2023
Q1 | $6.13M | Buy |
569,329
+24,992
| +5% | +$329K | ﹤0.01% | 2543 |
|
|
2022
Q4 | $8.15M | Buy |
544,337
+20,864
| +4% | +$304K | ﹤0.01% | 2391 |
|
|
2022
Q3 | $6.72M | Sell |
523,473
-7,996
| -2% | -$91.1K | ﹤0.01% | 2512 |
|
|
2022
Q2 | $5.15M | Buy |
531,469
+12,175
| +2% | +$114K | ﹤0.01% | 2685 |
|
|
2022
Q1 | $5.16M | Sell |
519,294
-13,923
| -3% | -$148K | ﹤0.01% | 2781 |
|
|
2021
Q4 | $6.28M | Buy |
533,217
+56,822
| +12% | +$698K | ﹤0.01% | 2763 |
|
|
2021
Q3 | $5.43M | Buy |
476,395
+17,536
| +4% | +$228K | ﹤0.01% | 2863 |
|
|
2021
Q2 | $6.39M | Buy |
458,859
+35,950
| +9% | +$546K | ﹤0.01% | 2754 |
|
|
2021
Q1 | $7.83M | Buy |
422,909
+44,427
| +12% | +$909K | ﹤0.01% | 2522 |
|
|
2020
Q4 | $6.69M | Buy |
378,482
+31,593
| +9% | +$555K | ﹤0.01% | 2423 |
|
|
2020
Q3 | $5.31M | Buy |
346,889
+111,903
| +48% | +$2.1M | ﹤0.01% | 2362 |
|
|
2020
Q2 | $5.99M | Buy |
234,986
+30,837
| +15% | +$644K | ﹤0.01% | 2228 |
|
|
2020
Q1 | $3.16M | Buy |
204,149
+13,631
| +7% | +$213K | ﹤0.01% | 2422 |
|
|
2019
Q4 | $2.11M | Buy |
190,518
+24,617
| +15% | +$214K | ﹤0.01% | 2972 |
|
|
2019
Q3 | $1.41M | Buy |
165,901
+3,792
| +2% | +$41.9K | ﹤0.01% | 3105 |
|
|
2019
Q2 | $2.19M | Buy |
162,109
+12,013
| +8% | +$186K | ﹤0.01% | 2896 |
|
|
2019
Q1 | $2.71M | Buy |
150,096
+53,345
| +55% | +$1.03M | ﹤0.01% | 2675 |
|
|
2018
Q4 | $2.72M | Sell |
96,751
-372
| -0.4% | -$7.76K | ﹤0.01% | 2587 |
|
|
2018
Q3 | $2.48M | Buy |
+97,123
| New | +$1.89M | ﹤0.01% | 2775 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
Geode Capital Management's KNSA Position: Q2 2026 in Review
Geode Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 1,263% in Q2 2026, buying an estimated $29M and bringing the position to 604,180 shares worth $38.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1767.
Geode Capital Management first reported a position in KNSA in Q3 2018 and has held it in 32 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- Geode Capital Management held 604,180 shares of Kiniksa Pharmaceuticals worth $38.6M as of Q2 2026.
- Geode Capital Management bought 559,860 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $29M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1767 holding.
- Geode Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.